Literature DB >> 17606709

Transcriptional functionality of germ line p53 mutants influences cancer phenotype.

Paola Monti1, Yari Ciribilli, Jennifer Jordan, Paola Menichini, David M Umbach, Michael A Resnick, Lucio Luzzatto, Alberto Inga, Gilberto Fronza.   

Abstract

PURPOSE: The TP53 tumor suppressor gene encodes a sequence-specific transcription factor that is able to transactivate several sets of genes, the promoters of which include appropriate response elements. Although human cancers frequently contain mutated p53, the alleles as well as the clinical expression are often heterogeneous. Germ line mutations of TP53 result in cancer proneness syndromes known as Li-Fraumeni, Li-Fraumeni--like, and nonsyndromic predisposition with or without family history. p53 mutants can be classified as partial deficiency alleles or severe deficiency alleles depending on their ability to transactivate a set of human target sequences, as measured using a standardized yeast-based assay (see http://www.umd.be:2072/index.html). We have investigated the extent to which the functional features of p53 mutant alleles determine clinical features in patients who have inherited these alleles and have developed cancer. EXPERIMENTAL
DESIGN: We retrieved clinical data from the IARC database (see http://www.p53.iarc.fr/Germline.html) for all cancer patients with germ line p53 mutations and applied stringent statistical evaluations to compare the functional classification of p53 alleles with clinical phenotypes.
RESULTS: Our analyses reveal that partial deficiency alleles are associated with a milder family history (P = 0.007), a lower numbers of tumors (P = 0.007), and a delayed disease onset (median, 31 versus 15 years; P = 0.007) which could be related to distinct tumor spectra.
CONCLUSIONS: These findings establish for the first time significant correlations between the residual transactivation function of individual TP53 alleles and clinical variables in patients with inherited p53 mutations who develop cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606709      PMCID: PMC2128783          DOI: 10.1158/1078-0432.CCR-06-2545

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  33 in total

1.  Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.

Authors:  Yuichi Kakudo; Hiroyuki Shibata; Kazunori Otsuka; Shunsuke Kato; Chikashi Ishioka
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

2.  Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast.

Authors:  J M Flaman; V Robert; S Lenglet; V Moreau; R Iggo; T Frebourg
Journal:  Oncogene       Date:  1998-03-12       Impact factor: 9.867

3.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.

Authors:  R L Ludwig; S Bates; K H Vousden
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

4.  Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Authors:  Kenneth P Olive; David A Tuveson; Zachary C Ruhe; Bob Yin; Nicholas A Willis; Roderick T Bronson; Denise Crowley; Tyler Jacks
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

5.  Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

Authors:  Gene A Lang; Tomoo Iwakuma; Young-Ah Suh; Geng Liu; V Ashutosh Rao; John M Parant; Yasmine A Valentin-Vega; Tamara Terzian; Lisa C Caldwell; Louise C Strong; Adel K El-Naggar; Guillermina Lozano
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

6.  A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Authors:  Gareth L Bond; Wenwei Hu; Elisabeth E Bond; Harlan Robins; Stuart G Lutzker; Nicoleta C Arva; Jill Bargonetti; Frank Bartel; Helge Taubert; Peter Wuerl; Kenan Onel; Linwah Yip; Shih-Jen Hwang; Louise C Strong; Guillermina Lozano; Arnold J Levine
Journal:  Cell       Date:  2004-11-24       Impact factor: 41.582

7.  Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.

Authors:  C J Di Como; C Prives
Journal:  Oncogene       Date:  1998-05-14       Impact factor: 9.867

8.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice.

Authors:  Geng Liu; John M Parant; Gene Lang; Patty Chau; Arturo Chavez-Reyes; Adel K El-Naggar; Asha Multani; Sandy Chang; Guillermina Lozano
Journal:  Nat Genet       Date:  2003-12-21       Impact factor: 38.330

9.  Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.

Authors:  S Rowan; R L Ludwig; Y Haupt; S Bates; X Lu; M Oren; K H Vousden
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

10.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

Authors:  J M Birch; A L Hartley; K J Tricker; J Prosser; A Condie; A M Kelsey; M Harris; P H Jones; A Binchy; D Crowther
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

View more
  24 in total

1.  Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Authors:  Paola Monti; Chiara Perfumo; Alessandra Bisio; Yari Ciribilli; Paola Menichini; Debora Russo; David M Umbach; Michael A Resnick; Alberto Inga; Gilberto Fronza
Journal:  Mol Cancer Res       Date:  2011-02-22       Impact factor: 5.852

2.  Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes.

Authors:  Michael F Walsh; Deborah I Ritter; Chimene Kesserwan; Dmitriy Sonkin; Debyani Chakravarty; Elizabeth Chao; Rajarshi Ghosh; Yelena Kemel; Gang Wu; Kristy Lee; Shashikant Kulkarni; Dale Hedges; Diana Mandelker; Ozge Ceyhan-Birsoy; Minjie Luo; Michael Drazer; Liying Zhang; Kenneth Offit; Sharon E Plon
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

3.  Aggregate penetrance of genomic variants for actionable disorders in European and African Americans.

Authors:  Pradeep Natarajan; Nina B Gold; Alexander G Bick; Heather McLaughlin; Peter Kraft; Heidi L Rehm; Gina M Peloso; James G Wilson; Adolfo Correa; Jonathan G Seidman; Christine E Seidman; Sekar Kathiresan; Robert C Green
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

4.  Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.

Authors:  Jennifer J Jordan; Alberto Inga; Kathleen Conway; Sharon Edmiston; Lisa A Carey; Lin Wu; Michael A Resnick
Journal:  Mol Cancer Res       Date:  2010-04-20       Impact factor: 5.852

5.  A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity.

Authors:  Sylwia Kabacik; Ana Ortega-Molina; Alejo Efeyan; Paul Finnon; Simon Bouffler; Manuel Serrano; Christophe Badie
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

6.  Within-Cluster Resampling for Analysis of Family Data: Ready for Prime-Time?

Authors:  Hemant K Tiwari; Amit Patki; David B Allison
Journal:  Stat Interface       Date:  2010-04-01       Impact factor: 0.582

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 8.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

9.  p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma.

Authors:  Lucja Fiszer-Maliszewska; Bernarda Kazanowska; Joanna Padzik
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

10.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis.

Authors:  Bernard Leroy; Jean Louis Fournier; Chikashi Ishioka; Paola Monti; Alberto Inga; Gilberto Fronza; Thierry Soussi
Journal:  Nucleic Acids Res       Date:  2012-11-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.